Pharmaceutical Business review

Gilead Q2 revenues up

Gilead Sciences‘ net income was $746.23m, compared to $712.06m for the same period in the prior year.

The company’s income from operations was $1.02bn for the second quarter ended 30 June 2011, as compared to $992.63m for the same period in 2010.

For the six months ended 30 June 2011 total revenue were $4.06bn, compared to $4.01bn for the same period in 2010.

Net income was $1.4bn for the six months ended 30 June 2011, as compared to $1.57bn for the same period prior year.

For the six months ended 30 June 2011, the company’s income from operations were $1.92bn , as compared to $2.15bn for the same period in 2010.